{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:27:36Z","timestamp":1784291256395,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although rare diseases (RD) are increasingly becoming a priority for healthcare activities and services around the world, developing research policy for investigating RD in public settings proves challenging due to the limited nature of existing evidence. Rare conditions require the involvement of a wide range of stakeholders in order to promote general awareness and garner political support. Consequently, it is critically important to identify trends in the various types of research focusing on rare disease stakeholders, including the specific topics or issues to be included in surveys and studies focused on RD stakeholders. This systematic review and thematic analysis analyses the existing literature based on RD surveys, including the stakeholders involved, and proposes potential research priorities and initiatives for policy-making related to RD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Articles were downloaded and analyzed from across five electronic databases (PubMed, EMBASE, Cochrane Central, Web of Science, and CINHAL) and 115 studies were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across 115 studies, the main research participants were patients and\/or caregivers (n\u2009=\u200977, 67.0%), health professionals (n\u2009=\u200918, 15.7%), and the public (n\u2009=\u20097, 6.1%). The studies discussed RDs in general (n\u2009=\u200946, 40.0%), endocrine, nutritional, and metabolic diseases (n\u2009=\u200920, 17.4%) and other RDs. Experiences with RD were examined by more than half of the selected studies (n\u2009=\u200974, 64.3%), followed by the opinions of stakeholders (n\u2009=\u200924, 20.9%). Most of the studies used surveys in order to collect relevant data (n\u2009=\u2009114, 99.1%). Additionally, the majority of the studies were conducted in high-income countries (n\u2009=\u200992, 80.0%) and rarely in middle and low-income countries (n\u2009=\u200912, 13.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Stakeholder research on RD reveals that there are significant instances of unmet needs and various challenges faced by the medical system in dealing with RDs.<\/jats:p>\n                    <jats:p>Furthermore, public awareness and support is critical to ensuring political feasibility of increasing national-level investments for RDs and development of medical products and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02892-2","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:02:25Z","timestamp":1700733745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Soho","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-In","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mahmud","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-9745","authenticated-orcid":false,"given":"Hannah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Wasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2892_CR1","unstructured":"EURORDIS. What is a rare disease? [Internet]. EURORDIS. 2009 [cited 2021 Mar 5]. Available from: https:\/\/www.eurordis.org\/about-rare-diseases."},{"key":"2892_CR2","unstructured":"de Vrueh R, Baekelandt ER, de Haan JM. Background Paper 6.19 Rare Diseases. 2013."},{"key":"2892_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2015;119:964\u201379. https:\/\/doi.org\/10.1016\/j.healthpol.2014.12.016.","journal-title":"Health Policy"},{"key":"2892_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/gt.2017.29","volume":"24","author":"D Julkowska","year":"2017","unstructured":"Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, et al. The importance of international collaboration for rare diseases research: A European perspective. Gene Ther. 2017;24:562\u201371. https:\/\/doi.org\/10.1038\/gt.2017.29.","journal-title":"Gene Ther"},{"key":"2892_CR5","doi-asserted-by":"publisher","unstructured":"Courbier S, Dimond R, Bros-Facer V. Share and protect our health data: An evidence based approach to rare disease patients\u2019 perspectives on data sharing and data protection\u2014Quantitative survey and recommendations. Orphanet J Rare Dis. 2019. https:\/\/doi.org\/10.1186\/s13023-019-1123-4","DOI":"10.1186\/s13023-019-1123-4"},{"key":"2892_CR6","unstructured":"Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe\u2019s Challenges. Brussels; 2008."},{"key":"2892_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11606-014-2895-9","volume":"29","author":"LP Forsythe","year":"2014","unstructured":"Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014;29:788\u2013800.","journal-title":"J Gen Intern Med"},{"key":"2892_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/bmjqs-2020-011219","volume":"30","author":"VT Tran","year":"2021","unstructured":"Tran VT, Diard E, Ravaud P. Priorities to improve the care for chronic conditions and multimorbidity: a survey of patients and stakeholders nested within the ComPaRe e-cohort. BMJ Qual Saf. 2021;30:577\u201387.","journal-title":"BMJ Qual Saf"},{"key":"2892_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-015-0598-0","volume":"16","author":"S MacLennan","year":"2015","unstructured":"MacLennan S, Bekema HJ, Williamson PR, Campbell MK, Stewart F, MacLennan SJ, et al. A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey. Trials. 2015;16:1\u201310.","journal-title":"Trials"},{"key":"2892_CR10","unstructured":"Commission of the European Communities. Together for Health: A Strategic Approach for the EU 2008\u20132013. White Pap. 2007."},{"key":"2892_CR11","doi-asserted-by":"crossref","unstructured":"Kusi G, Boamah Mensah AB, Boamah Mensah K, Dzomeku VM, Apiribu F, Duodu PA, et al. The experiences of family caregivers living with breast cancer patients in low-and middle-income countries: a systematic review. Systw Rev. 2020; 9(1):1\u20138","DOI":"10.1186\/s13643-020-01408-4"},{"issue":"2-3","key":"2892_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.healthpol.2012.02.018","volume":"105","author":"K Budych","year":"2012","unstructured":"Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter Exploring role behavior and its impact on patient-physician interaction. Health Policy. 2012;105(2\u20133):154\u201364.","journal-title":"Health Policy"},{"key":"2892_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1075-8","volume":"14","author":"L Vandeborne","year":"2019","unstructured":"Vandeborne L, Van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet J Rare Dis. 2019;14:1\u201311.","journal-title":"Orphanet J Rare Dis"},{"key":"2892_CR14","unstructured":"UK Bioindustry Association. Public attitudes to rare diseases\u202f: The case for equal access [Internet]. 2021. Available from: https:\/\/www.bioindustry.org\/uploads\/assets\/028a205c-b7a3-4b49-979d0fd6b8b4b81f\/66d925c6-ba70-47cd-ba01381f2ecec23c\/BIOJ8941-Public-Attitudes-Rare-Diseases-210617.pdf"},{"key":"2892_CR15","unstructured":"Kole A, Hedley V. Recommendations from the Rare 2030 Foresight Study: The future of rare diseases starts today. 2021."},{"issue":"1","key":"2892_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2176\/nmc.st.2016-0135","volume":"57","author":"Y Kanatani","year":"2017","unstructured":"Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir. 2017;57(1):1\u20137. https:\/\/doi.org\/10.2176\/nmc.st.2016-0135.","journal-title":"Neurol Med Chir"},{"key":"2892_CR17","unstructured":"Rare Voices Australia. National Strategic Action Plan for Rare Diseases. Australian Government Department of Health. 2020. http:\/\/www.rarevoices.org.au\/page\/167\/national-strategic-action-plan-for-rare-diseases"},{"key":"2892_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ajhg.2017.04.003","volume":"100","author":"KM Boycott","year":"2017","unstructured":"Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, et al. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Am J Hum Genet. 2017;100:695\u2013705.","journal-title":"Am J Hum Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02892-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02892-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02892-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:04:58Z","timestamp":1700733898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02892-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02892-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1908263\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the interpretation of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}